BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hesperos Inc. - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://hesperosinc.com
X-WR-CALDESC:Events for Hesperos Inc.
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20250902T130000
DTEND;TZID=UTC:20250902T143000
DTSTAMP:20260423T135042
CREATED:20250829T195357Z
LAST-MODIFIED:20250829T195357Z
UID:3201-1756818000-1756823400@hesperosinc.com
SUMMARY:WC13 2025: Hesperos CEO Presents "Utilization of human on a chip systems for rare disease regulatory submissions"
DESCRIPTION:Track:  Accelerating rare disease therapeutics via adoption of human biology-based non-clinical drug development in global north and global south countries\nHuman Health – Replacement \nSession Chair \nJanette Turner – Humane World for Animals\n\nSession Speakers \n\nAbstract 553\nUtilization of human on a chip systems for rare disease regulatory submissions\nLawrence Florin\, Hesperos\, Inc.\nAbstract 323\nModelling cardiac arrhythmias with human induced pluripotent stem cells\nAntonio Carvalho\, Federal Univ. Rio de Janeiro\nAbstract 459\nMultiparametric screening of MASH clinical candidates in human liver spheroids predicts clinical outcomes and reveals potential novel combinations for anti-steatotic and anti-fibrotic therapies.\nMadhu Lal-Nag\, https://insphero.com/\nAbstract 464\nAccelerating the development of Complex In Vitro Models (CIVMs) for rare disease therapeutics in India\nFrancesca Pistollato\, Humane World for Animals Europe\n\n\nSession Description\nRare diseases represent a significant disease burden and impact up to 10% of the world’s population. In particular\, south Asian countries experience higher rates of rare genetic disorders which has been attributed to traditional marriage practices of endogamy and consanguinity. Despite this\, there are no approved treatments for almost 95% of rare diseases. While the use of genetically engineered animal models is traditionally considered as one of the main strategies for rare disease therapeutics\, these model systems have often proven unsuitable for providing human-relevant insights into the patho-mechanisms of rare diseases. Recently\, efficacy data from a microphysiological system developed using human cells were used to support the authorisation of a clinical study for chronic inflammatory demyelinating polyneuropathy\, a rare neuromuscular disease. This\, and several other examples\, highlight the potential of complex in vitro models (CIVMs)\, including induced pluripotent stem cell (iPSCs)\, organoids\, and organs-on-chips\, to provide personalized model systems for understanding the biological mechanisms and assessing drug efficacy for rare diseases. \nThis workshop will include two sessions. The first session will aim to provide a global perspective on the status quo of the use and development of complex in vitro models to support drug development of rare diseases. We will hear from experts from around the world who have successfully used CIVMs to demonstrate drug efficacy and learn more about the challenges faced across different global regions. This would include talks on successful case studies that have used CIVMs to test the efficacy of repurposed drugs and progress to clinical trials\, general overview of how industry is currently using these systems in their internal drug development pipeline for rare diseases. The session would also include two talks from global south country-perspective where the higher cost of rare disease treatments also renders it inaccessible to most of the population\, highlighting the need for his would be followed by a session where it would be discussed how these insights from rare diseases could be used to develop a generalised framework for efficacy testing for other disease categories. We hope to develop a white/status paper covering the recommendations that emerge from these sessions. \nSession organization (90 minutes) \nSession 1: Human preclinical models for rare disease therapeutics- Status quo and challenges (45 minutes)\n1. Introduction– How CIVMs can provide a personalized system for efficacy testing\, general statement of needs or challenges (Suggested Speaker: James Hickman\, Hesperos Inc. – we have reached out to Dr Hickman and he has shown interest\, yet to accept)\n2. Case study – Developing efficacy models for cystic fibrosis using lung-on-a-chip (Suggested Speaker: Roberto Plebani\, Emulate. Inc)\n3. Accelerating the development of CIVMs for rare disease therapeutics in India: Not for profit speaker (Suggested speaker: Surat Parvatam\, HSI/India) \nSession 2: Breakout session on developing a generalized framework for incorporating CIVMs for efficacy testing based on insights from rare diseases (45 minutes)\nThis breakout session will focus on discussions on how strategies and insights from efficacy modelling for rare diseases can assist in creating a generalised framework for incorporating CIVMs into efficacy modelling of other disease models.
URL:https://hesperosinc.com/event/wc13-2025-hesperos-ceo-presents-utilization-of-human-on-a-chip-systems-for-rare-disease-regulatory-submissions/
LOCATION:Riocentro Convention Center\, Av. Salvador Allende\, 6555 - Barra Olímpica\, Rio de Janeiro\, Brazil
CATEGORIES:Invited Speaker
ATTACH;FMTTYPE=image/jpeg:https://hesperosinc.com/wp-content/uploads/2025/08/Screenshot-2025-08-29-135151.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250922
DTEND;VALUE=DATE:20250926
DTSTAMP:20260423T135042
CREATED:20250609T154351Z
LAST-MODIFIED:20250610T130827Z
UID:3124-1758499200-1758844799@hesperosinc.com
SUMMARY:23rd Annual Discovery on Target
DESCRIPTION:23rd Annual Discovery on Target\nSept. 22-25 \nInvited Speaker  \nJames Hickman\, PhD\, Hesperos Co-Founder and Chief Scientist \nRegulatory Acceptance of Human-on-a-Chip Platforms \nSept. 22\, 9:00 AM EST \nAbout Discovery on Target: This week long event in Boston\, MA showcases the latest research on current and emerging drug targets and technology.  There will be numerous presentations\, discussions\, and networking opportunities for those at the forefront of drug discovery. \nLearn more and register at https://www.discoveryontarget.com/
URL:https://hesperosinc.com/event/23rd-annual-discovery-on-target/
LOCATION:Sheraton Boston
CATEGORIES:Invited Speaker
ATTACH;FMTTYPE=image/jpeg:https://hesperosinc.com/wp-content/uploads/2025/06/DOT-banner-LI-standard-speaking-at-code.jpg
END:VEVENT
END:VCALENDAR